
Annual report 2025
added 02-12-2026
Baxter International Financial Statements 2011-2026 | BAX
Annual Financial Statements Baxter International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
9.65 B | 17.3 B | 20.4 B | 20.2 B | 42.8 B | 40 B | 46.1 B | 38.3 B | 39 B | 25.6 B | 19.9 B | 20.7 B | 20.4 B | 20.3 B | 17.1 B |
Shares |
513 M | 510 M | 506 M | 504 M | 502 M | 509 M | 509 M | 534 M | 543 M | 546 M | 545 M | 542 M | 543 M | 551 M | 569 M |
Historical Prices |
18.8 | 33.9 | 40.4 | 40.1 | 85.2 | 78.6 | 81.1 | 63.1 | 61.4 | 41.6 | 35.4 | 36 | 33.2 | 31 | 22.4 |
Net Income |
-957 M | -649 M | 2.66 B | -2.43 B | 1.28 B | 1.1 B | 1 B | 1.62 B | 717 M | 4.96 B | 968 M | 2.5 B | 2.01 B | 2.33 B | 2.22 B |
Revenue |
11.2 B | 10.6 B | 10.4 B | 10.1 B | 12.1 B | 11.7 B | 11.4 B | 11.1 B | 10.6 B | 10.2 B | 9.97 B | 16.7 B | 15.3 B | 14.2 B | 13.9 B |
Cost of Revenue |
7.86 B | 6.65 B | 6.21 B | 6.51 B | 7.43 B | 7.09 B | 6.6 B | 6.34 B | 6.11 B | 6.05 B | 5.78 B | 6.14 B | 5.25 B | 6.8 B | 6.85 B |
Gross Profit |
3.38 B | 3.98 B | 4.15 B | 3.55 B | 4.72 B | 4.59 B | 4.76 B | 4.78 B | 4.46 B | 4.11 B | 4.15 B | 8.16 B | 7.6 B | 7.3 B | 7.05 B |
Operating Income |
-308 M | 14 M | 707 M | -2.84 B | 1.35 B | 1.62 B | 1.77 B | 1.58 B | 1.29 B | 745 M | 573 M | 656 M | 496 M | - | - |
Interest Expense |
290 M | 408 M | 508 M | 413 M | 207 M | 153 M | 111 M | 93 M | 85 M | 89 M | 146 M | 167 M | 155 M | 113 M | 92 M |
EBITDA |
673 M | 1.01 B | 1.69 B | -1.77 B | 2.22 B | 2.44 B | 1.66 B | 2.43 B | 2.02 B | 1.52 B | 1.21 B | 3.71 B | 3.49 B | 3.53 B | 3.62 B |
Operating Expenses |
- | - | - | - | - | - | 3.88 B | 3.13 B | 3.2 B | 3.39 B | 3.7 B | 5.45 B | 4.93 B | 4.48 B | 4.1 B |
General and Administrative Expenses |
2.89 B | 2.97 B | 2.95 B | 3.1 B | 2.84 B | 2.47 B | 3.29 B | -48 M | 33 M | - | - | 4.03 B | - | 3.32 B | - |
All numbers in USD currency
Quarterly Income Statement Baxter International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
514 M | 513 M | 512 M | 510 M | 510 M | 508 M | 507 M | 506 M | 505 M | - | 504 M | 504 M | 503 M | - | 500 M | 503 M | 505 M | - | 511 M | 509 M | 507 M | - | 511 M | 510 M | 512 M | 528 M | 534 M | 535 M | 539 M | - | 545 M | 544 M | 541 M | - | 544 M | 548 M | 549 M | - | 546 M | 544 M | 543 M | - | 542 M | 542 M | 542 M | - | 543 M | 543 M | 545 M | - | 548 M | 550 M | 559 M | - | 566 M | 570 M | 577 M |
Net Income |
-46 M | 91 M | 126 M | 140 M | -314 M | 37 M | 2.51 B | -141 M | 44 M | - | -2.94 B | 252 M | 71 M | - | 450 M | 298 M | 298 M | 168 M | 356 M | 246 M | 332 M | -23 M | 369 M | 313 M | 342 M | 305 M | 518 M | 341 M | 382 M | -71 M | 251 M | 265 M | 272 M | 243 M | 130 M | 1.21 B | 3.38 B | 205 M | 1 M | 332 M | 430 M | 953 M | 468 M | 520 M | 556 M | 326 M | 544 M | 590 M | 552 M | 494 M | 583 M | 661 M | 588 M | 463 M | 576 M | 615 M | 570 M |
Revenue |
2.84 B | 2.81 B | 2.62 B | 2.7 B | 2.69 B | 2.49 B | 2.6 B | 3.71 B | 3.51 B | - | 3.61 B | 3.59 B | 3.71 B | - | 3.23 B | 3.1 B | 2.95 B | 3.18 B | 2.97 B | 2.72 B | 2.8 B | 3.04 B | 2.85 B | 2.83 B | 2.64 B | 2.83 B | 2.76 B | 2.81 B | 2.68 B | 2.77 B | 2.71 B | 2.6 B | 2.48 B | 2.64 B | 2.56 B | 2.58 B | 2.38 B | 2.6 B | 2.49 B | 2.48 B | 2.4 B | 2.79 B | 2.71 B | 4.15 B | 3.85 B | 4.32 B | 3.71 B | 3.67 B | 3.45 B | 3.75 B | 3.48 B | 3.57 B | 3.39 B | 3.59 B | 3.48 B | 3.54 B | 3.28 B |
Cost of Revenue |
1.88 B | 1.82 B | 1.76 B | 1.67 B | 1.66 B | 1.53 B | 1.54 B | 2.6 B | 2.24 B | - | 2.56 B | 2.22 B | 2.36 B | - | 1.9 B | 1.86 B | 1.8 B | - | 1.78 B | 1.68 B | 1.64 B | - | 1.62 B | 1.68 B | 1.56 B | 1.65 B | 1.53 B | 1.59 B | 1.57 B | - | 1.58 B | 1.47 B | 1.43 B | - | 1.49 B | 1.61 B | 1.41 B | - | 1.45 B | 1.45 B | 1.38 B | - | 1.52 B | 2.18 B | 1.96 B | - | 1.8 B | 1.73 B | 1.69 B | - | 1.67 B | 1.7 B | 1.67 B | - | 1.71 B | 1.7 B | 1.61 B |
Gross Profit |
950 M | 991 M | 861 M | 1.03 B | 1.03 B | 961 M | 1.06 B | 1.11 B | 1.28 B | - | 1.04 B | 1.37 B | 1.35 B | - | 1.32 B | 1.23 B | 1.14 B | 1.19 B | 1.2 B | 1.04 B | 1.16 B | 1.3 B | 1.23 B | 1.15 B | 1.08 B | 1.18 B | 1.23 B | 1.22 B | 1.12 B | 1.16 B | 1.13 B | 1.13 B | 1.04 B | 1.1 B | 1.07 B | 973 M | 966 M | 1.07 B | 1.03 B | 1.02 B | 1.02 B | 1.21 B | 1.19 B | 1.09 B | 1.09 B | 2 B | 1.91 B | 1.87 B | 1.7 B | 1.9 B | 1.81 B | 1.87 B | 1.71 B | 1.76 B | 1.77 B | 1.84 B | 1.68 B |
Operating Income |
172 M | 191 M | 58 M | 155 M | 179 M | 115 M | 179 M | -17 M | 129 M | - | -2.88 B | 264 M | 163 M | - | 513 M | 424 M | 390 M | - | 470 M | 331 M | 409 M | - | 503 M | 350 M | 383 M | 391 M | 382 M | 377 M | 434 M | - | 300 M | 347 M | 353 M | - | 186 M | 68 M | 188 M | - | 92 M | 87 M | 92 M | - | 217 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
7 M | - | 3 M | 1 M | 24 M | 9 M | 12 M | 132 M | 127 M | - | 109 M | 93 M | 88 M | - | 54 M | 37 M | 37 M | - | 42 M | 40 M | 30 M | - | 28 M | 28 M | 25 M | 33 M | 24 M | 24 M | 22 M | - | 22 M | 21 M | 20 M | - | 20 M | 16 M | 33 M | - | 38 M | 36 M | 35 M | - | 36 M | 47 M | 48 M | - | 51 M | 24 M | 31 M | - | 31 M | 27 M | 27 M | - | 23 M | 22 M | 22 M |
EBITDA |
262 M | 297 M | 305 M | 250 M | 252 M | 386 M | 326 M | 140 M | 442 M | - | -2.71 B | 457 M | 543 M | - | 1.16 B | 491 M | 607 M | - | 1.08 B | 732 M | 608 M | - | 1.08 B | 735 M | 575 M | 391 M | 968 M | 764 M | 624 M | - | 862 M | 725 M | 547 M | - | 785 M | 463 M | 377 M | - | 685 M | 464 M | 279 M | - | 809 M | 489 M | 236 M | - | 573 M | 366 M | 183 M | - | 534 M | 355 M | 175 M | - | 503 M | 327 M | 158 M |
General and Administrative Expenses |
708 M | 718 M | 703 M | 754 M | 723 M | 729 M | 744 M | 964 M | 995 M | - | 941 M | 970 M | 1.05 B | - | 680 M | 675 M | 627 M | - | 601 M | 590 M | 628 M | - | 627 M | 641 M | 601 M | 627 M | 684 M | 676 M | 633 M | - | 680 M | 630 M | 564 M | - | 726 M | 709 M | 641 M | - | 794 M | 783 M | 784 M | - | 827 M | 988 M | 910 M | - | 975 M | 838 M | 795 M | - | 743 M | 789 M | 752 M | - | 787 M | 765 M | 716 M |
All numbers in USD currency
Main types of financial statements Baxter International BAXFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Baxter International plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AtriCure
ATRC
|
$ 29.85 | 1.05 % | $ 1.43 B | ||
|
AngioDynamics
ANGO
|
$ 10.6 | -1.03 % | $ 433 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Harvard Bioscience
HBIO
|
$ 0.47 | -4.15 % | $ 19.9 M | ||
|
Alcon
ALC
|
$ 77.32 | -1.5 % | $ 40.4 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
ICU Medical
ICUI
|
$ 125.85 | -2.28 % | $ 3.1 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.31 | -0.85 % | $ 192 M | ||
|
iRhythm Technologies
IRTC
|
$ 113.0 | -1.46 % | $ 3.62 B | ||
|
Intuitive Surgical
ISRG
|
$ 472.16 | -1.48 % | $ 169 B | ||
|
The Cooper Companies
COO
|
$ 69.92 | -2.24 % | $ 13.9 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Glaukos Corporation
GKOS
|
$ 97.02 | -0.79 % | $ 4.7 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 159.36 | -0.17 % | $ 45.8 B | ||
|
Haemonetics Corporation
HAE
|
$ 59.92 | 0.72 % | $ 3.02 B | ||
|
electroCore
ECOR
|
$ 6.14 | -3.0 % | $ 33.9 K | ||
|
Masimo Corporation
MASI
|
$ 175.49 | -0.01 % | $ 9.35 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 11.56 | -2.12 % | $ 28 M | ||
|
Repro Med Systems
KRMD
|
$ 4.28 | -0.7 % | $ 198 M | ||
|
BioLife Solutions
BLFS
|
$ 18.36 | 1.16 % | $ 846 M | ||
|
Nephros
NEPH
|
$ 3.5 | -7.89 % | $ 36.4 M | ||
|
ResMed
RMD
|
$ 230.84 | -0.68 % | $ 33.7 B | ||
|
Retractable Technologies
RVP
|
$ 0.71 | 2.62 % | $ 21.3 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Merit Medical Systems
MMSI
|
$ 69.95 | 2.61 % | $ 4.14 B | ||
|
Envista Holdings Corporation
NVST
|
$ 24.61 | -3.26 % | $ 4.13 B | ||
|
STAAR Surgical Company
STAA
|
$ 18.84 | 2.45 % | $ 934 M | ||
|
Stereotaxis
STXS
|
$ 1.89 | 0.27 % | $ 172 M | ||
|
Teleflex Incorporated
TFX
|
$ 107.32 | -0.87 % | $ 4.79 B | ||
|
OraSure Technologies
OSUR
|
$ 2.97 | -3.88 % | $ 218 M | ||
|
LeMaitre Vascular
LMAT
|
$ 108.06 | 1.43 % | $ 2.45 B | ||
|
Utah Medical Products
UTMD
|
$ 63.28 | 1.02 % | $ 230 M | ||
|
Pro-Dex
PDEX
|
$ 48.46 | 3.5 % | $ 159 M | ||
|
Microbot Medical
MBOT
|
$ 2.69 | -1.47 % | $ 27.4 M | ||
|
West Pharmaceutical Services
WST
|
$ 235.46 | 1.89 % | $ 17 B | ||
|
Repligen Corporation
RGEN
|
$ 114.2 | 0.39 % | $ 6.36 M | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.54 | -2.2 % | $ 2.3 B | ||
|
Pulse Biosciences
PLSE
|
$ 21.57 | 1.27 % | $ 1.45 B | ||
|
STERIS plc
STE
|
$ 214.57 | 1.05 % | $ 21.2 B | ||
|
Milestone Scientific
MLSS
|
$ 0.28 | -3.75 % | $ 22.3 M |